Results from the first phase 1 clinical study of DR-01, a non-fucosylated anti-CD94 targeting antibody in patients with relapsed/refractory cytotoxic lymphomas: Dose escalation and optimization Meeting Abstract
| Authors: | Zain, J.; Iyer, S. P.; Marchi, E.; Gandhi, M.; Kim, Y. H.; Khodadoust, M. S.; Brammer, J. E.; Poh, C.; Porcu, P.; Dilley, K.; Will, M.; Kantor, A.; Leonowens, C.; Tomasevic, N.; Prince, H. M.; Horwitz, S. |
| Abstract Title: | Results from the first phase 1 clinical study of DR-01, a non-fucosylated anti-CD94 targeting antibody in patients with relapsed/refractory cytotoxic lymphomas: Dose escalation and optimization |
| Meeting Title: | 66th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 144 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2024 Dec 7-10 |
| Meeting Location: | San Diego, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2024-11-05 |
| Start Page: | 980 |
| End Page: | 982 |
| Language: | English |
| ACCESSION: | WOS:001478592100024 |
| DOI: | 10.1182/blood-2024-206053 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- Source: Wos |
